UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

Annals of oncology, 2016-08, Vol.27 (8), p.1525-1531

2016

Volltextzugriff (PDF)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

British journal of cancer, 2013-03, Vol.108 (5), p.1052-1060

2013

Volltextzugriff (PDF)

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Annals of oncology, 2008-09, Vol.19 (9), p.1547-1552

2008

Volltextzugriff (PDF)

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Volltextzugriff (PDF)

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Annals of oncology, 2015-02, Vol.26 (2), p.320-325

2015

Volltextzugriff (PDF)

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

BMC cancer, 2019-11, Vol.19 (1), p.1029-1029, Article 1029

2019

Volltextzugriff (PDF)

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European journal of cancer (1990), 2018-04, Vol.93, p.19-27

2018

Volltextzugriff (PDF)

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study

European journal of cancer (1990), 2017-11, Vol.86, p.82-90

2017

Volltextzugriff (PDF)

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Annals of oncology, 2017-04, Vol.28 (4), p.754-760

2017

Volltextzugriff (PDF)

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

European journal of cancer (1990), 2017-09, Vol.82, p.230-236

2017

Volltextzugriff (PDF)

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Annals of oncology, 2024-08, Vol.35 (8), p.718-727

2024

Volltextzugriff (PDF)

Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al

Annals of oncology, 2015-06, Vol.26 (6), p.1269-1270

2015

Volltextzugriff (PDF)

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

Annals of oncology, 2010-09, Vol.21 (9), p.1765-1771

2010

Volltextzugriff (PDF)

A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer

Breast cancer research and treatment, 2023-02, Vol.198 (1), p.23-29

2023

Volltextzugriff (PDF)

Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns

Breast (Edinburgh), 2021-04, Vol.56, p.S37-S38

2021

Volltextzugriff (PDF)

Endpoints in cancer clinical trials

Journal of visceral surgery, 2014-02, Vol.151 (1), p.17-22

2014

Volltextzugriff (PDF)

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

ESMO open, 2021-06, Vol.6 (3), p.100134-100134, Article 100134

2021

Volltextzugriff (PDF)

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay

European journal of surgical oncology, 2017-05, Vol.43 (5), p.921-930

2017

Volltextzugriff (PDF)

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

Oncoimmunology, 2018-05, Vol.7 (5), p.e1424673-e1424673

2018

Volltextzugriff (PDF)

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Annals of oncology, 2013-10, Vol.24 (10), p.2630-2635

2013

Volltextzugriff (PDF)

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2046-2052

2016

Volltextzugriff (PDF)

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial

Annals of oncology, 2014-08, Vol.25 (8), p.1563-1570

2014

Volltextzugriff (PDF)

Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii69-viii69

2018

Volltextzugriff (PDF)

Diffusion prophylactic axillary irradiation in breast cancer - Literature review

Cancer radiothérapie, 2021-04, Vol.25 (2), p.191-199

2021

Volltextzugriff (PDF)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Annals of oncology, 2010-12, Vol.21 (12), p.2305-2315

2010

Volltextzugriff (PDF)

1 – 25 von 345

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(327)
Mit Volltextzugriff
(314)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(103)
Life Sciences & Biomedicine
(95)
Science & Technology
(95)
Oncology
(88)
Female
(79)
Middle Aged
(68)
Aged
(63)
Adult
(60)
Biological And Medical Sciences
(47)
Medical Sciences
(47)
Male
(43)
Hematology, Oncology And Palliative Medicine
(38)
Treatment Outcome
(38)
Chemotherapy
(36)
Breast Neoplasms - Drug Therapy
(34)
Breast Cancer
(33)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Pharmacology. Drug Treatments
(31)
Antineoplastic Agents
(28)
Life Sciences
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(99)
European Journal Of Cancer
(32)
Cancer Research
(31)
Journal Of Clinical Oncology
(23)
European Journal Of Cancer Supplements
(14)
Oncologie
(14)
Breast
(13)
British Journal Of Cancer
(11)
Cancer Radiothérapie
(7)
Bulletin Du Cancer
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

A propensity score–weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer

Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns

Endpoints in cancer clinical trials

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial

Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients

Diffusion prophylactic axillary irradiation in breast cancer - Literature review

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Suchergebnisse filtern